Related Experiment Video
Updated: Aug 11, 2026
Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
Published on: January 15, 2010
Dissociation between biochemical and behavioral recovery in MPTP-treated mice
F B Weihmuller1, M Hadjiconstantinou, J P Bruno
1Department of Psychology, College of Social and Behavioral Sciences, Ohio State University, Columbus 43210.
Abstract:
Injection of a low dose of haloperidol, that has no obvious behavioral effects in normal mice, produces akinesia, catalepsy, and somatosensory neglect in MPTP-treated mice. These neuroleptic-induced sensorimotor impairments are exhibited soon after MPTP treatments and coincide with a decrease in both striatal DA and DOPAC levels. DA and DOPAC content gradually return to near-control levels over a 3-5 month period. Interestingly, while the haloperidol-induced somatosensory deficits declined in parallel with the rise in DA and DOPAC levels, the motor deficits persisted for up to 5 months after MPTP administration. These data suggest subtle differences in the neurochemical mediation of these behaviors and that the persistence of neuronal impairments may not necessarily be revealed by near-normal transmitter levels.
Insights
Low-dose haloperidol causes motor and sensory deficits in mice treated with MPTP. While sensory impairments resolved as dopamine levels recovered, motor deficits persisted, suggesting lasting neuronal damage.
Area of Science:
- Neuroscience
- Neuropharmacology
- Behavioral Science
Background:
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin that selectively damages dopaminergic neurons, modeling Parkinson's disease.
- Haloperidol, a typical antipsychotic, can induce motor side effects.
Purpose of the Study:
- To investigate the effects of haloperidol on sensorimotor functions in MPTP-treated mice.
- To explore the relationship between neurochemical changes (dopamine and DOPAC levels) and behavioral deficits.
Main Methods:
- Mice were treated with MPTP to induce dopaminergic neurotoxicity.
- Low-dose haloperidol was administered to assess sensorimotor impairments.
- Striatal dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) levels were measured.
- Behavioral tests were conducted to evaluate motor and sensory functions.
Main Results:
- Haloperidol induced akinesia, catalepsy, and somatosensory neglect in MPTP-treated mice.
- These deficits correlated with decreased striatal DA and DOPAC levels.
- Somatosensory deficits improved as DA and DOPAC levels recovered.
- Motor deficits persisted for up to 5 months post-MPTP, despite normalized neurotransmitter levels.
Conclusions:
- Neuroleptic-induced sensorimotor impairments in MPTP-treated mice reveal distinct neurochemical underpinnings for different deficits.
- Persistent motor impairments suggest that normalized neurotransmitter levels may not fully reflect the extent of neuronal damage or functional recovery.
